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Germline mutations in the fumarate hydratase gene
(FH) predispose to multiple cutaneous and uterine leio-
myoma syndrome (MCL) and MCL associated with
renal cell cancer. MCL is inherited in an autosomal
dominant pattern, manifesting as skin leiomyoma and
uterine ¢broids in a¡ected individuals. Fumarate hydratase,
a component of the tricarboxylic acid cycle, acts as a
tumor suppressor gene in the development of cutaneous
and uterine leiomyoma and renal cell cancer in this
syndrome. Here we report the clinical and muta-
tional analysis of ¢ve families with MCL, with the
identi¢cation of ¢ve new mutations a¡ecting highly con-
served residues of the FH protein. These results provide
further evidence for the role of the FH gene in
the pathogenesis of MCL. Keywords: leiomyoma/renal cell
cancer. J Invest Dermatol 121:741 ^744, 2003
C
utaneous leiomyomas are rare, benign tumors aris-
ing from the arrector pili muscle of hair follicles.
Multiple cutaneous and uterine leiomyoma syn-
drome (MCL; MIM #150800), in which a¡ected
individuals develop associated skin and uterine leio-
myomas, is a disorder inherited in an autosomal dominant pat-
tern. The skin lesions usually appear between the early teens and
the fourth decade of life. For the majority of a¡ected women,
uterine ¢broids of early onset usually require hysterectomy or
myomectomy (Stewart, 2001). In some families with MCL, the
disease is associated with an additional predisposition to type II
papillary renal cell carcinoma (Launonen et al, 2001).
The genetic locus for MCL was recently mapped to chromo-
some 1q42.3-43 (Alam et al, 2001; Kiuru et al, 2001; Martinez-Mir
et al, 2002) and subsequently, mutations in the fumarate hydratase
gene (FH) were identi¢ed (Tomlinson et al, 2002). The gene pro-
duct for FH is fumarate hydratase, part of the tricarboxylic acid
cycle involved in energy production for the cell. Dominant mu-
tations in FH cause MCL in approximately 59.5% of a¡ected in-
dividuals (Tomlinson et al, 2002). Based on its role in MCL, FH
has been hypothesized to act as a tumor suppressor gene in spora-
dic tumors as well. However, two recent reports show a very low
frequency of FH mutations in di¡erent types of tumors, includ-
ing uterine and cutaneous leiomyomas, leiomyosarcoma, and re-
nal cell carcinoma (Barker et al, 2002; Kiuru et al, 2002).Whether
FH plays a role in sporadic tumorigenesis remains to be deter-
mined. Mutations in three di¡erent subunits of succinate dehy-
drogenase, another enzyme of the tricarboxylic acid cycle, also
correlate with a high incidence of tumors, in particular, heredi-
tary paragangliomas (Baysal et al, 2001). Interestingly, autosomal
recessive mutations in the FH gene have been implicated in
fumarate hydratase de¢ciency, which presents with progressive
encephalopathy and developmental delay (MIM #606812).
Accordingly, Tomlinson et al (2002) reported a patient with fu-
marase de¢ciency whose mother, a carrier for an FH mutation,
developed skin leiomyoma. How these two phenotypically dis-
tinct disorders are linked to di¡erent types and combinations of
mutations in FH calls for further investigation.
In this study, we report the clinical and mutational analysis of
¢ve families with MCL.We have identi¢ed ¢ve new mutations in
the FH gene, further supporting the role of FH in MCL.
MATERIALS ANDMETHODS
Human subjects We have identi¢ed ¢ve families with dominantly
inherited MCL, comprising 16 a¡ected individuals available for this study.
Blood samples were collected according to the local Institutional Review
Board. Clinical features and pedigrees of four families were previously
published in case reports (MCL-1, MCL-2, MCL-3, and MCL-5) (Lun
and Spelman, 2000; Tsoitis et al, 2001; Alam et al, 2002; Martinez-Mir et al,
2002).
Mutation analysis Genomic DNA was isolated from peripheral blood
collected in EDTA-containing tubes using the PureGene DNA isolation
kit (Gentra Systems, Minneapolis, MN). To screen for mutations in the
human FH gene, all exons and splice junctions were PCR-ampli¢ed from
genomic DNA. PCR primers are shown in Table I. PCR products
were sequenced in an ABI Prism 310 automated sequencer, using the
ABI Prism BigDye terminator cycle sequencing ready reaction kit
(PE Applied Biosystems, Foster City, CA), following puri¢cation in
Centri£ex gel ¢ltration cartridges (Edge Biosystems, Gaitherburg, MD).
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Mutations were identi¢ed by visual inspection and comparison with
control sequences generated from unrelated una¡ected individuals.
To con¢rm the mutations identi¢ed, direct and mismatched PCRwere
used. The nonsense mutation Q142X and the missense H275Y and V351L
were con¢rmed by digestion of the corresponding PCR products with
BstNI, BspHI, and MaeIII, respectively. In the case of S115I, a reverse
mismatched primer (50 -CCT AAC ATT TCA ATT GCT CTA TAG-30)
was used to introduce an Alu I restriction site. Finally, the PCR product
corresponding to frameshift mutation 1081del4 was run on a poly-
acrylamide gel and visualized by ethidium bromide staining.
All ¢ve DNAvariants were tested in a mixed control population of 46^
49 individuals. The missense variants S115I, H275Y, and V351L were tested
in an additional sample of 32^43 control individuals.
RESULTS
Clinical ¢ndings The patients in the ¢ve families with MCL
(Fig 1) originated in ¢ve di¡erent countries, namely, two Jewish
families from Tunisia (MCL-1) and Ethiopia (MCL-4), Greece
(MCL-2), Australia (MCL-3), and Puerto Rico (MCL-5). They
comprised a total of 11 and 5 a¡ected women and men,
respectively. Skin leiomyomas were found in 14 individuals, 9
women and 5 men, ranging in age from 14 to 55 y. The a¡ected
patients reported sensitivity of the lesions to cold temperature
and touch. Two of the female patients exhibited skin
leiomyomas alone, without any uterine abnormality. The typical
skin lesions are ¢rm, skin colored to red, ranging from a few in
number to approximately 100 in older individuals (Fig 2). The
lesions range between 0.2 and 1.0 cm in diameter and cluster
with time.
Of the 9 women with uterine leiomyoma, 7 had coexisting skin
leiomyoma and 2 had uterine leiomyoma alone. Six of these
patients with a¡ected uteri eventually underwent hysterectomy
or myomectomy.
Mutation analysis in the FH gene We have analyzed ¢ve
families with dominantly inherited MCL for FH mutations. All
were found to carry heterozygous mutations in the FH gene
(Table II). None of these mutations have been previously
reported in patients with MCL or fumarate hydratase de¢ciency,
and each of themwas unique to a single family.The fact that they
have not been detected in the control population excludes them
as common polymorphisms.
A C4T transition at nucleotide position 553, which results in
the nonsense mutation Q142X (amino acid residue 185 in the
mitochondrial isoform), was identi¢ed in family MCL-2, and a
deletion of four nucleotides in exon 7 was found in family MCL-
Table I. PCR primers for ampli¢cation of the FH gene
Exon Forward primer Reverse primer Size (bp)
1 CCCAGAAATTCTACCCAAGC AGGGCTGAAGGTCACTGC 214
2 TGATCCTGGGTTTCTTTTCAAC ATGAATACAGCCTACTTCATCC 240
3 CCAAAATAATAAACTTCCATGC ATGGGTCTGAGGTTATTAAG 221
4 CTGTATTCAAACTCTGTGGC TTATAACCAAAAAACAGCAAAGC 288
5 GTTTTTGTTGCCTCTGATTTAAC TGGCCATTTGTACCAAGCTC 290
6 GAGTAACTTGTAAGCTATTAGG AATGTACAGACCACGTA 285
7 TAACTTGTTCACCCATCTAGG CTAGTCAAGTTTTAGCTCCAAC 287
8 TTAGTCTTTACTCTGTCATTGG TAATAAGCCTTTGGTCAAAAAAC 212
9 ATTGTATATTTACTGTCAACCAG AAACACTGATCCACTTGTCTCT 356
10 CTGCTAACCCATATGTCGTC CGTTTTTAAGAAATGGGAGTCTG 252
Figure 1. Pedigrees with MCL. Black, gray, and empty symbols, a¡ected, unknown, and una¡ected family members, respectively. Asterisks, individuals whose
blood samples were available, except in MCL-1where blood samples for most family members were available.
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5. This frameshift mutant allele is the result of a 4-bp deletion
starting at any position between nucleotides 1081^1083, creating
a premature termination codon 12 amino acids downstream of
the deletion site. Three missense mutations were also identi¢ed:
a G4T transversion at nucleotide position 473 in exon 4,
leading to the missense mutation S115I (mitochondrial amino
acid residue 158; family MCL-4), a C4T transition at position
952 in exon 7 resulting in the missense mutation H275Y
(mitochondrial amino acid residue 318; family MCL-1), and a
G4C transversion at position 1180 in exon 8, creating the
missense mutation V351L (mitochondrial amino acid residue
394; family MCL-3). Exon number and nucleotide positions are
derived from the FH sequence (Accession No. 18549070). The
amino acid position for the cytosolic isoform is given, for
comparison with the previously reported mutations (Tomlinson
et al, 2002;Table II).
DISCUSSION
In this study, we have identi¢ed ¢ve new FH ‘‘mutations’’ in
MCL families, further supporting the role of this housekeeping
gene in tumorigenesis. The nature of these mutations, including
non-sense, frameshift, and missense mutations, clearly supports
the role of the FH gene in MCL. Nonetheless, the involvement
of a housekeeping gene such as FH in tumorigenesis unveils new
questions about the etiologic mechanism underlying MCL.
Our study has identi¢ed a heterozygous nonsense (Q142X)
and a frameshift mutation (1081del4) in two of the families. The
most likely fate of the mRNA of these mutant alleles would be
nonsense-mediated mRNA decay, where the nonsense-bearing
mRNA is recognized and degraded soon after transcription
(Frischmeyer and Dietz, 1999). Unfortunately, mRNA samples
from these families were not available for further testing and
therefore other possible mechanisms such as translation into a
truncated protein or exon skipping cannot be ruled out.
Regarding the three missense changes identi¢ed in our study,
S115I (MCL-4), H275Y (MCL-1), andV351L (MCL-3), the possi-
bility of these being rare polymorphisms cannot be completely
excluded, because a mixed control population was used owing
to unavailability of a su⁄cient number of ethnically matched
controls. This is especially true for V531L, where both amino
acids consist of hydrophobic side chains with only one carbon
di¡erence. It is noteworthy, however, that 7 of the 17 mutations
reported byTomlinson et al (2002) were also missense mutations.
The a¡ected amino acid residues S115, H275, and V351 are con-
served among human, pig, rat, and mouse FH.
Cosegregation between the mutations and the MCL pheno-
type was con¢rmed for families MCL-1 (H275Y) and MCL-3
(V351L), for which blood samples from several a¡ected family
members were available. These two missense variants show re-
duced penetrance for the skin and uterine lesions. H275Y was
identi¢ed in family MCL-1 (Fig 1), in which we had previously
performed linkage studies (Martinez-Mir et al, 2002). Restriction
analysis in all family members showed that 12 individuals, 7 wo-
men and 5 men, were heterozygous for the mutation. Of the 7
carrier women, 4 presented with both skin and diagnosed or sus-
pected uterine lesions (hysterectomy in III-17 and III-19, diag-
nosed myoma in IV-12, and menorrhagia in V-12), 2 presented
with skin lesions alone (III-21 and IV-2), and 1 was an asympto-
matic female (V-2). With the exception of V-17, all carrier men
su¡ered from skin leiomyomata.Thus, only two young asympto-
matic carriers were identi¢ed,V-2 (age 19) and V-17 (age 18).V-17
was reported to carry the disease-associated haplotype during our
studies to re¢ne theMCUL1 locus (Martinez-Mir et al, 2002).V-2,
on the other hand, showed a key recombination event within the
disease-associated haplotype (Martinez-Mir et al, 2002). Owing to
the fact that V-2 was an una¡ected individual and that the loca-
tion and identity of the causative gene was still unknown at the
time these studies were performed, her carrier status as an asymp-
tomatic carrier or una¡ected could not be established.With the
identi¢cation of the FH gene byTomlinson et al (2002), we con-
¢rmed that V-2 did indeed carry the disease-associated haplotype
and, as shown here, an FH mutation.
In family MCL-3 (Fig 1), on the other hand, the V351L mis-
sense substitution was present in three women, one of them with
both uterine and skin involvement and the remaining two with
only uterine myoma.The grandmother in this family, reported to
have uterine polyps on a biopsy report, did not carry the muta-
tion. For family MCL-2 (Q142X; Fig 1) the mutation was only
present in the a¡ected individual and his mother and absent in
the una¡ected father and sibling. Since no family history of
MCL was reported for the a¡ected member of this family, the
carrier mother will be reexamined for skin and uterine lesions.
The missense variant S115I in family MCL-4 was present in the
a¡ected family member only and absent in the remaining three
una¡ected siblings (Fig 1). The parents of these individuals were
not available for the study. Finally, only one individual from fa-
mily MCL-5 (Figs 1, 2), an a¡ected woman, was available for
examination and was heterozygous for the frameshift mutation.
None of the families studied here su¡ered from any other type
of tumor, including papillary renal cell cancer.
In summary, of 11 female patients, 7 exhibited concurrent skin
and uterine leiomyoma involvement. Of the remaining 4 a¡ected
female patients, 2 had skin lesions only and 2 had uterine leio-
myoma alone. Patients from the same family may display di¡er-
ent phenotypic expression of the disease. For example, in family
MCL-3, a mother with uterine leiomyoma and no skin lesions
had two daughters, one with both skin and uterine lesions and
the other with uterine involvement only.
Seventeen of 42 families reported byTomlinson et al (2002) did
not display mutations in the FH gene.The rate of mutation detec-
tion in our study, on the other hand, reached 100%. Tomlinson
et al (2002) performed single-strand conformation polymorphism
and conformation-speci¢c gel electrophoresis as mutation detec-
tion methods in some of their families versus direct sequencing in
Table II. Germline FH mutations in MCL families
Family
Wild-type
sequence
Mutant
sequence
Amino-acid
changea Exon
MCL-4 AGC ATC S115I 4
MCL-2 CAG TAG Q142X 4
MCL-1 CAT TAT H275Y 7
MCL-5 GAAAATG-
AACCA
GAAAACCA 4-bp del between amino
acids 318 and 319
7
MCL-3 GTC CTC V351L 8
aAmino-acid positions are derived from the cytosolic enzyme sequence (468
amino acids). The exon number corresponds to the entire gene; exon 1 encodes
the 43 amino acids that form the mitochondrial signal peptide and the ¢rst amino
acid of the cytosolic protein.
Figure 2. Clinical picture of cutaneous leiomyoma. Clustering of
skin leiomyoma lesions can be observed on upper back (A) and arm (B).
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our study. This could account for the lower mutation rate in the
original report. Overall, it still remains possible that the predis-
position to MCL is genetically heterogeneous.
One of the implications of gene identi¢cation for inherited
susceptibility to tumorigenesis is the possible role they may play
in the more common sporadic presentation of the same type of
tumors. Families with MCL present with benign skin and uter-
ine leiomyomas, the latter being a major public health issue. In
addition, the aggressive papillary renal cell carcinoma can also
be associated with MCL, as well as leiomyosarcoma (Launonen
et al, 2001). Based on this hypothesis, two groups have recently
searched for mutations in the FH gene in di¡erent types of tu-
mors. Kiuru et al (2002) have analyzed a total of 200 sporadic
tumors, including uterine and cutaneous leiomyomas, leiomyo-
sarcomas, and papillary renal cell carcinomas. However, only ¢ve
FH mutations were identi¢ed. Barker et al (2002), on the other
hand, studied 26 leiomyosarcomas and 129 uterine leiomyomas.
In this case, no FH mutations were identi¢ed, although LOH
for 1q and 1q42-43 was detected in 50 and 5% of leiomyosarco-
mas and leiomyomas, respectively. Collectively, these data sug-
gests either that FH does not play a major role in the deve-
lopment of sporadic tumors or that the pathologic mechanism
of FH in MCL involves events di¡erent from somatic mutations.
The identi¢cation of the particular FH mutation in each MCL
family will allow for close follow-up of those individuals at risk
for the development of the aggressive papillary renal cell cancer
(Kiuru et al, 2001; Launonen et al, 2001). Establishing the etiologic
mechanisms of MCL may facilitate development of new thera-
peutic options for a¡ected patients.
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